COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

T1 Mapping in HIV Patients With High and Low CD4+ Cell Counts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02054494
Recruitment Status : Unknown
Verified December 2015 by Claas P. Naehle, University Hospital, Bonn.
Recruitment status was:  Recruiting
First Posted : February 4, 2014
Last Update Posted : December 11, 2015
Information provided by (Responsible Party):
Claas P. Naehle, University Hospital, Bonn

Brief Summary:

HIV-infection is associated with an increased risk for cardiovascular disease. Especially patients with low CD4+ counts have a higher incidence of structural heart disease. Myocardial T1 relaxation time, as well as T1-derived extracellular volume fraction are relatively new methods for non-invasive myocardial tissue characterization, including diffuse myocardial fibrosis.

In our study HIV-patients with high and low CD4+ counts are examined on a 3T MRI scanner (Ingenia 3T, Philips Medical, Best, Netherlands). Scanning protocol includes common SSFP sequences, STIR imaging and LGE [Late gadolinium enhancement]. All HIV patients are treated in the HIV outpatient clinic of the hospital's Internal Medicine department and have an unremarkable history of cardiac disease. Patients are recruited from all over Germany. In order to obtain reference values, a subgroup of healthy, age-matched controls is included in this study.

Aim of this study is to show differences in T1- and ECV-values in the investigated subgroups. In addition, we also want to create cut-off values for healthy and affected myocardium in asymptomatic HIV-infected patients. This study could show whether myocardial T1 mapping is a potential screening parameter for beginning heart disease as part of an HIV-infection, and whether an application in routine diagnostic is reasonable.

Condition or disease
Heart Diseases HIV

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Myocardial T1-mapping and T1-derived Extracellular Volume Fraction (ECV) in HIV-infection Patients With Chronic High and Low CD4+ Counts and in a Healthy Control Group
Study Start Date : July 2013
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

HIV patients with high CD4+ cell counts
HIV Infection, Chronic high CD4+ cell counts (>500 /μl), No known cardiac disease
HIV patients with low CD4+ cell counts
HIV Infection, Chronic low CD4+ cell counts (<200 /μl), No known cardiac disease
Control Group
No known cardiac disease.

Primary Outcome Measures :
  1. Native T1 Relaxation Times [ Time Frame: Measurement will be performed within 2 weeks after MRI scan ]
    T1 relaxation times will be directly obtained form the T1 maps through ROI analysis. T1 maps will be analyzed using a segmental approach. T1 relaxation times are given in [ms].

Secondary Outcome Measures :
  1. Extracellular volume fraction (ECV) [ Time Frame: Measurement will be performed within 2 weeks after MRI scan ]

    Hematocrit corrected ECV will be calculated using pre- and post-contrast T1 values for myocardium and blood pool using following formula:

    ECV= (1⁄T1 "myocardium post contrast"-1⁄T1 "myocadium pre contrast")/(1⁄T1 "blood post contrast"-1⁄ T1 "blood pre contrast") x (1-hematocrit).

    ECV is given in percentage.

Other Outcome Measures:
  1. Cardiac function and aortic distensibility [ Time Frame: Measurement will be performed within 2 weeks after MRI scan ]

    Cardiac function (left ventricular endsystolic volume (LV-ESV), left ventricular enddiastolic volume (LV-EDV), and left ventricular ejection fraction (LV-EF)) will be determined offline using a dedicated software (ViewForum, Philips Healthcare, Best, The Netherlands). LV-ESV and LV-EDV will be quantified manually by tracing the endocardial borders. LV-EF is given in percentage. LV-ESV and LV-EDV are given in [ml].

    Aortic Distensibility will be calculated as:

    Distensibility(10^-3 mmHg^-1 )=(Amax−Amin)/Amin x (Sys−Dias),where Amax and Amin represent the maximal and minimal cross-sectional area of the aorta on cine CMR images, and Sys and Dias represent the systolic and diastolic blood pressures (in millimetres of mercury), respectively.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
HIV patients are recruted from the HIV outpatients clinic of our hospital.

Inclusion Criteria:

  • chronic HIV infection
  • no known cardiac disease
  • no cardiovascular risk factors

Exclusion Criteria:

  • contraindications to MRI (e.g. metal implants)
  • chronic kidney disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02054494

Layout table for location contacts
Contact: Julian A Luetkens, MD +4928828714414
Contact: Claas P Naehle, MD

Layout table for location information
University of Bonn, Dept. of Radiology Recruiting
Bonn, NRW, Germany, 53127
Contact: Claas P Naehle, MD   
Contact: Julian A Luetkens, MD   
Principal Investigator: Claas P Naehle, MD         
Sponsors and Collaborators
University Hospital, Bonn
Layout table for investigator information
Principal Investigator: Claas P Naehle, MD University of Bonn, Dept. of Radiology, Sigmund-Freud-Str. 25, 53127 Bonn, Germany

Layout table for additonal information
Responsible Party: Claas P. Naehle, PD Dr. med., University Hospital, Bonn Identifier: NCT02054494    
Other Study ID Numbers: 038/13
First Posted: February 4, 2014    Key Record Dates
Last Update Posted: December 11, 2015
Last Verified: December 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Cardiovascular Diseases